Literature DB >> 10754501

A possible divergent role for the oestrogen receptor alpha and beta subtypes in clinical breast cancer.

J M Knowlden1, J M Gee, J F Robertson, I O Ellis, R I Nicholson.   

Abstract

We have examined the relative levels of oestrogen receptor beta (ERbeta) mRNA in 94 breast cancer specimens using a semi-quantitative RT-PCR procedure. We correlated its expression with ERalpha and various clinical, pathological and biochemical features of the disease. The level of ERbeta mRNA expression in these samples was found to be much lower than ERalpha. Although ERalpha mRNA species were found to be most frequently associated with histological grade I and II tumours, displaying tubular differentiation, low grades of nuclear pleomorphism and low mitotic activity, such features were not characteristic of ERbeta positive samples. Indeed, application of the Spearman rank correlation test revealed that there was an inverse association between ERbeta normalised levels and ERalpha protein HScore. Also ERbeta mRNA positive cancers were more frequently EGFR protein positive than their negative counterparts (p = 0.016), a feature normally associated with endocrine-insensitive disease. Our data suggest that although ERbeta levels are most likely lower than ERalpha, they may influence the biological behaviour of breast cancers containing low levels of ERalpha. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10754501     DOI: 10.1002/(sici)1097-0215(20000320)89:2<209::aid-ijc17>3.0.co;2-6

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  10 in total

Review 1.  Tamoxifen resistance in breast cancer: elucidating mechanisms.

Authors:  L C Dorssers; S Van der Flier; A Brinkman; T van Agthoven; J Veldscholte; E M Berns; J G Klijn; L V Beex; J A Foekens
Journal:  Drugs       Date:  2001       Impact factor: 9.546

2.  Expression and prognostic value of estrogen receptor β in patients with triple-negative and triple-positive breast cancer.

Authors:  Liying Guo; Qianwen Zhu; Mulati Aisimutuola; Dilimina Yilamu; Sha Liu; Adina Jakulin
Journal:  Exp Ther Med       Date:  2015-03-23       Impact factor: 2.447

3.  Expression and prognostic value of estrogen receptor beta in breast cancer patients.

Authors:  Liying Guo; Qianwen Zhu; Dilimina Yilamu; Adina Jakulin; Sha Liu; Ting Liang
Journal:  Int J Clin Exp Med       Date:  2014-10-15

4.  ERβ Isoforms Have Differential Clinical Significance in Breast Cancer Subtypes and Subgroups.

Authors:  Young Choi; Hadong Kim; Simcha Pollack
Journal:  Curr Issues Mol Biol       Date:  2022-04-06       Impact factor: 2.976

5.  The favourable prognostic value of oestrogen receptor beta immunohistochemical expression in breast cancer.

Authors:  L Nakopoulou; A C Lazaris; E G Panayotopoulou; I Giannopoulou; N Givalos; S Markaki; A Keramopoulos
Journal:  J Clin Pathol       Date:  2004-05       Impact factor: 3.411

6.  Gene expression markers in circulating tumor cells may predict bone metastasis and response to hormonal treatment in breast cancer.

Authors:  Haiying Wang; Julian Molina; John Jiang; Matthew Ferber; Sandhya Pruthi; Timothy Jatkoe; Carlo Derecho; Yashoda Rajpurohit; Jian Zheng; Yixin Wang
Journal:  Mol Clin Oncol       Date:  2013-08-02

7.  The Possible Impact of Obesity on Androgen, Progesterone and Estrogen Receptors (ERα and ERβ) Gene Expression in Breast Cancer Patients.

Authors:  R Jahanban Esfahlan; N Zarghami; A Jahanban Esfahlan; M Mollazadeh; K Nejati; M Nasiri
Journal:  Breast Cancer (Auckl)       Date:  2011-11-14

8.  Hepatic Metabolism of Sakuranetin and Its Modulating Effects on Cytochrome P450s and UDP-Glucuronosyltransferases.

Authors:  Hyesoo Jeong; Jimin Lee; Soolin Kim; Yoo Yeon Yeo; Hyunyoung So; Honghua Wu; Yun Seon Song; Chang-Young Jang; Hee-Doo Kim; Min Jung Kim; Minsun Chang
Journal:  Molecules       Date:  2018-06-26       Impact factor: 4.411

9.  A divergent role for estrogen receptor-beta in node-positive and node-negative breast cancer classified according to molecular subtypes: an observational prospective study.

Authors:  Flavia Novelli; Michele Milella; Elisa Melucci; Anna Di Benedetto; Isabella Sperduti; Raffaele Perrone-Donnorso; Letizia Perracchio; Irene Venturo; Cecilia Nisticò; Alessandra Fabi; Simonetta Buglioni; Pier Giorgio Natali; Marcella Mottolese
Journal:  Breast Cancer Res       Date:  2008-09-04       Impact factor: 6.466

10.  PAR1 is selectively over expressed in high grade breast cancer patients: a cohort study.

Authors:  Norma A Hernández; Elma Correa; Esther P Avila; Teresa A Vela; Víctor M Pérez
Journal:  J Transl Med       Date:  2009-06-18       Impact factor: 5.531

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.